Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Characterization of pan-fungal monoclonal antibodies targeting Aspergillus

NIH View original grant

The fungal pathogen Aspergillus poses a significant health threat to individuals with weakened immune systems, pre-existing lung disease, and pulmonary co-infections, causing an estimated 2.1 million cases of life-threatening invasive aspergillosis (IA) annually, and approximately 1.8 million deaths (85% mortality). Recent estimates indicate that the frequency of IA has dramatically risen both domestically and globally in recent decades. Even with medical treatment, IA has a disproportionally hi

Matching Reagent Categories (10)

Anti-Aspergillus Surface Antigen Antibodies

Antibodies recognizing Aspergillus cell-surface antigens for binding assays, surface localization studies, and comparison with NXT-2-directed antifungal antibodies.

1 products found

Opsonophagocytic Killing Assay Reagents for Aspergillus

Reagents to support opsonophagocytic killing assays, including fungal targets and immunologic assay components for testing antibody-mediated enhancement of Aspergillus clearance in vitro.

1 products found

Aspergillus fumigatus Binding and Opsonophagocytic Killing Assay Reagents

Reagents for in vitro binding and opsonophagocytic killing studies with A. fumigatus, including tools suitable for evaluating antibody-mediated fungal clearance mechanisms.

1 products found

Epitope Mapping Kits for Antibody Characterization

Products for fine epitope mapping and antibody-antigen interaction analysis to define NXT-2 antifungal epitopes and rank monoclonal antibodies by specificity and affinity-related properties.

1 products found

ELISA and Binding Assay Kits for Antibody Characterization

Assay kits and reagents for measuring antibody-antigen binding, affinity, and specificity during down-selection of NXT-2 monoclonal antibodies with the strongest anti-Aspergillus activity.

1 products found

Publications from this Grant

You are here:
Blank Blank Blank Blank
Blank Blank Blank Blank
Chat with us!